Meftal maker says adverse reaction flagged by IPC is very rare
Blue Cross Laboratories, the owner of the Meftal painkiller brand, has clarified that the adverse reaction the Indian Pharmacopoeia Commission (IPC) has flagged is a rare event. The company claims that the product's constituent, mefenamic acid, can cause adverse reactions, including eosinophilia and systemic symptoms (DRESS) syndrome.
Disclaimer : Mytimesnow (MTN) lets you explore worldwide viral news just by analyzing social media trends. Tap read more at source for full news. The inclusion of any links does not necessarily imply any endorsement of the views expressed within them.
